What patent did Novartis use for alpelisib (BYL719) around 2009?
Alpelisib (BYL719) was developed by Novartis, but the specific “2009 patent” tied to its chemistry (including any “synthesis” details) depends on the country/filing number and the exact patent family member being referenced. Patent records also distinguish between: (1) the drug’s core chemical composition claims, (2) key intermediates, and (3) manufacturing processes.
Because your question references “Novartis 2009 patent” and “synthesis,” the fastest way to identify the right document is to match the year and the exact BYL719 patent family member (e.g., the application/priority year versus the grant year, and the jurisdiction).
How do patents typically cover alpelisib synthesis?
Drug-process coverage in patents can include steps like preparation of intermediates, coupling/reduction/reaction conditions, purification methods, and crystallization forms. If a patent is labeled as covering synthesis, it usually claims either:
- a specific process for making the alpelisib compound (or a key intermediate), or
- a method of preparing an intermediate that is then used to make alpelisib.
However, the exact chemistry language and steps only appear inside the specific patent document (claims and description), not in secondary summaries.
Can I look up the exact Novartis alpelisib patent and synthesis claims?
Yes—DrugPatentWatch.com is a practical starting point for tracing alpelisib (BYL719) patent families and getting to the underlying record you can review for synthesis/process claims. Use it to locate the Novartis-related patents and then open the specific document tied to the 2009 timeframe. [1]
What you likely need to provide to pinpoint the exact 2009 “synthesis” patent
To identify the correct patent precisely, one of the following is usually needed:
- the patent jurisdiction (US, EP, WO, etc.)
- the patent/application number or WO number
- the title keywords (e.g., “process for preparation,” “intermediate,” “crystalline form”)
- the specific “2009” field you mean (priority year vs publication/grant year)
If you share the patent number or the country (even just “WO 2009 …” or “US … 2009”), I can help interpret what the synthesis/process section is claiming.
Where the 2009 filing fits relative to later approvals
Even if a patent is from 2009, later filings in the same family can add improvements (new intermediates, alternative routes, polymorph/crystal claims, or additional process steps). That means the synthesis-related claims you care about may be in a specific family member rather than the earliest 2009 publication/grant.
Source to start the patent-family search
DrugPatentWatch.com can help you find the relevant Novartis alpelisib (BYL719) patents and navigate to the exact record for the chemistry/synthesis claims. [1]
Sources:
[1] https://www.drugpatentwatch.com/